Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients | NEJM
Original Article from The New England Journal of Medicine — Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Related Articles
‘This is revolutionary!’: Breakthrough cholesterol treatment can cut levels by 69% after one dose | BBC Science Focus Magazine
The future of heart attack prevention could be as easy as a single injection
Strokes and Heart Attacks Kill. New Drugs Are Coming to Prevent Them.
Heart attacks and strokes remain the world’s biggest killers. This year, we’ll see test results on new cardiovascular treatments that cut cholesterol even more than…
‘This is revolutionary!’: Breakthrough cholesterol treatment can cut levels by 69% after one dose | BBC Science Focus Magazine
The future of heart attack prevention could be as easy as a single injection
‘Safer’ CRISPR: Base Editing Breaks Through in the Clinic as Beam, Verve Advance
Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative to conventional CRISPR. Clinical results have…
Verve’s 2nd swing at PCSK9 editing yields clean safety profile, teeing up Lilly opt-in decision
Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. | Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. One year…
Verve’s 2nd swing at PCSK9 editing yields clean safety profile, teeing up Lilly opt-in decision
Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. | Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. One year…
Verve’s 2nd swing at PCSK9 editing yields clean safety profile, teeing up Lilly opt-in decision
Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. | Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. One year…
LPA Variants, Risk of Coronary Disease, and Estimated Clinical Benefit of Lipoprotein(a)-Lowering Therapies
This mendelian randomization analysis estimates the magnitude of the change in plasma lipoprotein(a) levels needed to have the same evidence of an association with coronary…
Metsera, Maze secure combined $415 million in IPOs
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go public.
Events | Verve Therapeutics
The Investor Relations website contains information about Verve Therapeutics’s business for stockholders, potential investors, and financial analysts.